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Efavirenz Pharmacokinetics and
Pharmacodynamics in HIV-Infected Persons
Receiving Rifapentine and Isoniazid for
Tuberculosis Prevention
Anthony T. Podany,1 Yajing Bao,2 Susan Swindells,3 Richard E. Chaisson,4 Janet W. Andersen,2 Thando Mwelase,5
Khuanchai Supparatpinyo,6 Lerato Mohapi,7 Amita Gupta,8 Constance A. Benson,9 Peter Kim,10 and Courtney V. Fletcher1,3;
for the AIDS Clinical Trials Group A5279 Study Team
1College of Pharmacy, University of Nebraska Medical Center, Omaha; 2Statistical and Data Analysis Center, Harvard School of Public Health, Boston,
Massachusetts; 3Infectious Diseases, Internal Medicine, University of Nebraska Medical Center, Omaha; 4Center for Tuberculosis Research, Johns
Hopkins University School of Medicine, Baltimore, Maryland; 5University of the Witwatersrand, Johannesburg, South Africa; 6Research Institute for Health
Sciences and Faculty of Medicine, Chiang Mai University, Thailand; 7University of the Witwatersrand and Baragwanath Hospital, Soweto, South Africa;
8Center for Clinical Global Health Education, Johns Hopkins University School of Medicine, Baltimore, Maryland; 9Antiviral Research Center, University of
California, San Diego; and 10Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
Background. Concomitant use of rifamycins to treat or prevent tuberculosis can result in subtherapeutic con-
centrations of antiretroviral drugs. We studied the interaction of efavirenz with daily rifapentine and isoniazid in
human immunodeficiency virus (HIV)–infected individuals receiving a 4-week regimen to prevent tuberculosis.
Methods. Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations
at baseline and weeks 2 and 4 of concomitant therapy. Efavirenz apparent oral clearance was estimated and the geo-
metric mean ratio (GMR) of values before and during rifapentine and isoniazid was calculated. HIV type 1 (HIV-1)
RNA was measured at baseline and week 8.
Results. Eighty-seven participants were evaluable: 54% were female, and the median age was 35 years (interquartile
range [IQR], 29–44 years). Numbers of participants with efavirenz concentrations≥1 mg/L were 85 (98%) at week 0; 81
(93%) at week 2; 78 (90%) at week 4; and 75 (86%) at weeks 2 and 4. Median efavirenz apparent oral clearance was 9.3
L/hour (IQR, 6.42–13.22 L/hour) at baseline and 9.8 L/hour (IQR, 7.04–15.59 L/hour) during rifapentine/isoniazid
treatment (GMR, 1.04 [90% confidence interval, .97–1.13]). Seventy-nine of 85 (93%) participants had undetectable
HIV-1 RNA (<40 copies/mL) at entry; 71 of 75 (95%) participants had undetectable HIV-1 RNA at week 8. Two
participants with undetectable HIV-1 RNA at study entry were detectable (43 and 47 copies/mL) at week 8.
Conclusions. The proportion of participants with midinterval efavirenz concentrations ≥1 mg/L did not cross
below the prespecified threshold of >80%, and virologic suppression was maintained. Four weeks of daily rifapentine
plus isoniazid can be coadministered with efavirenz without clinically meaningful reductions in efavirenz
mid-dosing concentrations or virologic suppression.
Clinical Trials Registration. NCT 01404312.
Keywords. HIV/AIDS; tuberculosis; rifapentine; pharmacokinetics; pharmacodynamics.
Human immunodeficiency virus (HIV) and tuberculo-
sis are the leading causes of infection-related deaths
globally [1]. With access to antiretroviral therapy (ART),
HIV may become a manageable chronic disease. How-
ever, the presence of coinfection with tuberculosis leads
to an increased level of morbidity and mortality if left
untreated. In 2012, the World Health Organization
(WHO) estimated there were 320 000 deaths in HIV-
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infected individuals related to tuberculosis [1]. HIV-infected in-
dividuals with latent tuberculosis (LTBI) are 21–34 times more
likely to develop active tuberculosis than HIV-uninfected indi-
viduals [1]. Early detection and treatment of LTBI in HIV-
infected individuals is imperative.
Isoniazid has long been the cornerstone of treatment to pre-
vent active tuberculosis. However, current regimens are lengthy
and may be associated with adverse effects. Difficulties with ad-
herence to the current isoniazid recommendations lead to high
rates of therapy discontinuation and poor rates of completion
[2]. There is a compelling need to establish shorter and safer
treatment regimens for LTBI in HIV-infected individuals.
Recent data have shown that a 3-month regimen of once-
weekly rifapentine plus isoniazid is as effective as the current
standard of care, 9 months of daily isoniazid [3, 4]. However,
the US Centers for Disease Control and Prevention (CDC)
guidelines currently do not recommend use of a rifapentine-
containing regimen in HIV-infected individuals on ART
because possible drug–drug interactions with rifapentine
have not been fully evaluated [5]. Additionally, the Inter-
national Standards for Tuberculosis Care, developed by TB
CARE, which includes the WHO and the American Thoracic
Society, recommend using isoniazid preventive therapy over
rifapentine-containing regimens for treatment of LTBI in
high-prevalence areas in HIV-infected individuals [6].
Rifapentine is a known cytochrome P450 (CYP) enzyme in-
ducer [7, 8]. Efavirenz-based ART is a first-line treatment option
for HIV in both US and international guidelines [9–13]. Efavir-
enz is a CYP substrate, leading to concern for decreased efavirenz
concentrations and increased risk of virologic failure if dosed
concurrently with rifapentine. The pharmacokinetic characteris-
tics of this combination have not been evaluated. To this end, we
designed a study to evaluate the effect of daily rifapentine plus
isoniazid for 4 weeks on efavirenz pharmacokinetics.
METHODS
Study Population
The AIDS Clinical Trials Group (ACTG) study A5279 is an inter-
national, multicenter, randomized, open-label, phase 3 clinical
trial comparing a 4-week daily rifapentine and isoniazid regimen
with a standard 9-month daily isoniazid regimen for the preven-
tion of tuberculosis in HIV-infected participants without evi-
dence of active tuberculosis. An objective of A5279 was to
investigate the effects of concomitant rifapentine and isoniazid
administration on efavirenz pharmacokinetics and to determine
the proportions of participants who had acceptable efavirenz con-
centrations during concomitant administration of rifapentine and
isoniazid. Overall study inclusion criteria were as follows: HIV-
infected men and women at least 13 years of age and 30 kg
body weight, without evidence of active tuberculosis, who either
have a positive tuberculin skin test or interferon-γ release assay or
live in a high-burden area for tuberculosis (defined as prevalence
of at least 60 cases per 100 000 population). The first 90 study par-
ticipants taking an efavirenz-containing ART regimen for at least
4 weeks prior to study entry and randomized to the rifapentine
plus isoniazid arm of A5279 were enrolled in the pharmacokinet-
ic study. The institutional review boards or ethics committees of
the participating institutions approved the study, and each partic-
ipant gave written informed consent.
Randomization and Masking
Participants were randomly assigned to either 9 months of daily
isoniazid plus pyridoxine (vitamin B6), or 4 weeks of daily
weight-based rifapentine and isoniazid plus pyridoxine in an
open-label fashion.
Outcomes
The primary outcome of the pharmacokinetic study was the
proportion of participants with efavirenz plasma concentrations
≥1 mg/L while receiving daily rifapentine and isoniazid. The
threshold of ≥1 mg/L was selected because mid-dosing interval
concentrations <1 mg/L have been shown to increase the odds
of virologic failure [14].
A priori rules of adequate proportions of patients with accept-
able efavirenz plasma concentrations at both weeks 2 and 4 were
included in the study protocol. Efavirenz pharmacokinetic data
were judged to be acceptable if ≤20% of participants had efavir-
enz concentrations <1 mg/L at both weeks 2 and 4. Any partic-
ipant with a baseline (week 0; pre–rifapentine and isoniazid)
efavirenz plasma concentration <1 mg/L was taken as evidence
for efavirenz nonadherence and deemed not evaluable for the
purposes of the pharmacokinetic study.
Putative stopping rules were developed for the pharmacoki-
netic study should a large proportion of study participants have
unacceptable plasma concentrations of efavirenz while taking
the rifapentine and isoniazid. Pharmacokinetic data were eval-
uated after enrollment of 9, 21, 31, and 90 participants taking an
efavirenz-containing antiretroviral regimen. At each of these
enrollment milestones, the numbers of participants necessary
to have acceptable efavirenz concentrations at both weeks 2
and 4 according to the stopping rules were ≥4 of 9 participants,
≥12 of 21 participants, and ≥20 of 31 participants, respectively.
These rules were developed to have a high likelihood (≥95%) of
continuing to accrue participants if the true underlying rate of
having acceptable efavirenz concentrations is >80% [15].
The final evaluation occurred after 90 participants had been
enrolled in the pharmacokinetic study. In the final evaluation,
the exact lower 95% confidence bound was calculated for the
proportion of participants with efavirenz concentrations >1
mg/L during the 4 weeks of LTBI therapy. The efavirenz phar-
macokinetic data were deemed acceptable if the lower bound of
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the 95% confidence interval (CI) of the proportion of partici-
pants with acceptable efavirenz concentrations at both weeks
2 and 4 did not fall below the prespecified 80% level.
Procedures
Rifapentine dosing was based on body weight. Participants weigh-
ing 30–34.9 kg received 300 mg once daily, participants weighing
35–44.9 kg received 450 mg once daily, and participants weighing
≥45 kg received 600 mg once daily, administered as 150-mg tab-
lets. Rifapentine was provided by sanofi-aventis (France) and iso-
niazid from multiple manufacturers. Efavirenz was obtained from
local sources at each study site and was approved by national au-
thorities. Patients were instructed to take all doses orally with food.
The isoniazid dose was 300 mg, administered orally as a single tab-
let, daily with pyridoxine (vitamin B6) 25 mg; isoniazid was to be
taken together with rifapentine and food.
Plasma samples were collected for pharmacokinetic evalua-
tions at study entry (week 0, prior to initiation of rifapentine
and isoniazid) and again at week 2 and week 4 (during rifapen-
tine and isoniazid administration). A mid-dosing interval (12
hours postdose) plasma sample was collected for pharmacologic
evaluation of efavirenz concentrations. Additional plasma sam-
ples were collected at baseline and at week 8 (post–study drug
administration) for HIV type 1 (HIV-1) RNA quantitation. Efa-
virenz concentrations were quantified by validated ultra perfor-
mance liquid chromatography assays as previously described [16].
Pharmacokinetic parameter estimation was accomplished
using maximum a posteriori probability–Bayesian estimation im-
plemented in ADAPT II (Biomedical Simulations Resource at the
University of Southern California, Los Angeles) [17]. The prima-
ry pharmacokinetic parameter of interest for efavirenz was appar-
ent oral clearance. Population mean and standard deviation
values for efavirenz apparent oral clearance used in the Bayesian
analysis were 8.0 ± 4 L/hour, and were taken from published lit-
erature [18]. Week 0 efavirenz concentrations were used to esti-
mate the prerifapentine plus isoniazid apparent oral clearance of
efavirenz. Plasma concentrations from weeks 2 and 4 were taken
together to estimate the apparent oral clearance of efavirenz dur-
ing concomitant treatment with rifapentine and isoniazid.
Statistical Analysis
Descriptive statistics were used to summarize continuous vari-
ables, including age, CD4 counts, and efavirenz treatment dura-
tion at study entry. Categorical variables, including race/ethnicity,
country, whether HIV-1 RNA level was detectable, and ART at
study entry, were summarized by frequency distribution. Partic-
ipants with missing data were not included in the calculations.
Participants with randomized treatment temporarily held prior
to week 4 or incomplete pharmacokinetic evaluations were ex-
cluded from the analysis. Median and percentiles were used to
describe the collection time of pharmacokinetic samples post–
efavirenz dose and efavirenz concentration at weeks 0, 2, and
4. The geometric mean ratio (GMR) and 2-sided 90% CI of
the pre- and on-rifapentine and isoniazid apparent oral clearance
values were calculated. Analyses were done using SAS software,
version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
FromMay 2012 until May 2013, 97 HIV-infected individuals re-
ceiving efavirenz-containing ART were enrolled in the pharma-
cokinetic study from 5 countries: South Africa, Thailand, United
States, Botswana, and Peru. Seven participants had incomplete
(weeks 0, 2, and 4) PK sample collection. One participant was
hospitalized and did not complete the pharmacokinetic evalua-
tions. One participant had studymedication (rifapentine and iso-
niazid) held and thus did not complete the pharmacokinetic
study, and 1 participant was not included due to the clinic
inadvertently not storing a collected pharmacokinetic sample.
Eighty-seven participants had complete data sets (week 0, 2,
and 4) available for pharmacokinetic analyses (Table 1). The me-
dian age of the 87 participants was 35 years (interquartile range
[IQR], 29–44 years); 47 (54%) were female; 48 (55%) were black
non-Hispanic; and 37 (43%) and 31 (36%) of the participants
were from South Africa and Thailand, respectively.
Table 1. Baseline Demographic and Clinical Characteristics
Characteristic Total (N = 87)
Age, y, median (IQR) 35 (29–44)
Female sex 47 (54)
Race/ethnicity
White non-Hispanic 1 (1)
Black non-Hispanic 48 (55)
Hispanic (regardless of race) 6 (7)
Asian/Pacific Islander 32 (37)
Country of enrollment
Botswana 5 (6)
Peru 2 (2)
South Africa 37 (43)
Thailand 31 (36)
United States 12 (14)
HIV-1 RNA, log10 copies/mL
a
Mean (SD) 1.6 (0.2)
Min, Max 1.6, 3.0
Undetectable (<40 copies/mL) 79 (93)
Detectable 6 (7)
CD4 count, cells/µL, median (IQR) 508 (372–649)
EFV duration, wk, median (IQR) 109 (61–233)
Data are shown as No. (%) unless otherwise specified.
Abbreviations: EFV, efavirenz; HIV-1, human immunodeficiency virus type 1;
IQR, interquartile range; SD, standard deviation.
a Entry HIV-1 RNA was available for 85 of 87 evaluable participants.
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Samples for HIV-1 RNAwere collected from 85 of 87 partic-
ipants at baseline (week 0) and from 75 of 87 participants at
week 8 HIV. Seventy-nine of the 85 (93%) participants had un-
detectable (<40 copies/mL) plasma HIV-1 RNA at study entry.
Seventy-one of 75 (95%) participants with available week 8
HIV-1 RNA had a undetectable level (<40 copies/mL). Of 75
participants with HIV-1 RNA results at week 8, 71 had unde-
tectable HIV-1 RNA at entry. Two of these 71 (2.8%) had de-
tectable HIV-1 RNA (43 and 47 copies/mL) at week 8. The
median duration of efavirenz containing ART before study
entry was 109 weeks (IQR, 61–233 weeks).
Interim safety evaluations were conducted by assessing the
proportion of participants with acceptable efavirenz concentra-
tions when study enrollment reached 9, 21, and 31 evaluable
participants. As all passed their respective thresholds, the
study was allowed to enroll to full accrual.
Two hundred sixty-one pharmacokinetic samples (87 samples
at each week 0, 2, and 4) were collected at a median post–efavirenz
dose sampling time of 14.8 hours (IQR, 13.5–16.8 hours) at week
0, 14.0 hours (IQR, 12.8–15.6 hours) at week 2, and 13.7 hours
(IQR, 12.7–15.5 hours) at week 4 (Figure 1A). Median week 0
(efavirenz only, no rifapentine/isoniazid) efavirenz concentra-
tions were 2.59 mg/L (IQR, 1.85–3.83 mg/L). Median week 2
(efavirenz + rifapentine + isoniazid) efavirenz concentrations
were 2.46 mg/L (IQR, 1.47–3.81 mg/L), and median week 4
(efavirenz + rifapentine + isoniazid) efavirenz concentrations
were 2.54 mg/L (IQR, 1.44–3.83 mg/L). Eighty-five (98%) partic-
ipants had week 0 efavirenz plasma concentrations ≥1 mg/L, 81
(93%) participants had week 2 efavirenz plasma concentrations
≥1 mg/L, and 78 (90%) study participants had week 4 plasma
efavirenz concentrations ≥1 mg/L. Seventy-five (86%) partici-
pants had week 2 and week 4 plasma efavirenz concentrations
≥1 mg/L with a lower 95% CI bound of 78.6%. Excluding (as
per protocol) the 2 participants with efavirenz <1 mg/L at
entry, 75 of 85 (88.2%) had efavirenz ≥1 mg/L at both weeks 2
and 4 with a lower 95% CI bound of 80.8% (Figure 1B and
1C). The median apparent oral clearance of efavirenz was 9.3
L/hour (range, 1.0–33.4) for week 0, prior to initiation of rifapen-
tine and isoniazid, and 9.8 L/hour (range, .8–24.9) for combined
weeks 2 and 4, during rifapentine and isoniazid treatment
(Figure 1D). The GMR of efavirenz apparent oral clearance was
1.04 (on rifapentine and isoniazid to off rifapentine and isonia-
zid; 90% CI, .97–1.13).
DISCUSSION
In this study of coadministration of rifapentine and isoniazid for
4 weeks in HIV-infected persons receiving an efavirenz-containing
antiretroviral regimen, we found that 88% of participants main-
tained efavirenz concentrations above the minimum target con-
centration of 1 mg/L. A nonsignificant increase in the apparent
oral clearance of efavirenz was observed, consistent with the
well-known CYP induction properties of rifapentine [7, 8]. Of
those participants who had HIV-1 RNA <40 copies/mL at base-
line and an available week 8 HIV-1 RNA sample, 97% remained
at <40 copies/mL after completion of rifapentine and isoniazid
therapy. One limitation of the study was that week 8 HIV-1
RNA data were not available for 12 of the patients included in
Figure 1. Efavirenz (EFV) sampling times, hours postdose by week (A), EFV concentrations by week (B), EFV concentrations by week (truncated concen-
tration axis) (C), and EFV apparent oral clearance (CL/F) before and after rifapentine (RPT) and isoniazid administration (D).
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the pharmacokinetic study. However, week 8 HIV-1 RNA data
were available on 86% of the patients with complete pharmaco-
kinetic data available. The findings provide a pharmacokinetic
and pharmacodynamic basis to support 4 weeks of rifapentine
and isoniazid coadministration for prevention of tuberculosis
in HIV-infected persons also taking efavirenz.
The CDC currently recommends once-weekly directly ob-
served treatment with rifapentine and isoniazid for 12 weeks
as an alternative to 9 months of daily isoniazid for the treatment
of LTBI [5]. This recommendation is based on 3 randomized
clinical trials that have shown the shorter-course regimens to
be as effective as 9 months of daily isoniazid therapy [3, 4,
19]. Utilization rates of efavirenz-containing ART are high
in countries of high tuberculosis prevalence. The rifapentine-
isoniazid regimen, however, is not recommended for use in
HIV-infected persons receiving ART because potential drug–
drug interactions have not been evaluated. Efavirenz is metabo-
lized by CYP2B6 and CYP2A6 [20], and rifapentine, like rifampin,
is a known inducer of CYP-mediated drug metabolism, with the
potential to lower efavirenz concentrations [7, 8]. In contrast, iso-
niazid has been shown to inhibit CYP2A6, which may counteract
an induction effect of rifapentine in a select genotypic subset of
individuals [21]. The role of isoniazid in this 3-way drug–drug in-
teraction among rifapentine and efavirenz appears to better predict
and explain high efavirenz plasma concentrations, which may
cause patients to experience adverse drug effects from efavirenz,
as opposed to lower efavirenz concentrations, which may lead to
virologic failure [22–26]. With regard to the interaction between
efavirenz and rifampin, the US Department of Health and
Human Services guidelines for treatment of HIV infection suggest
an increased efavirenz dose of 800 mg daily as an option in pa-
tients receiving rifampin who weigh >60 kg [10]. Similarly, the
US Food and Drug Administration–approved package insert for
efavirenz recommends the higher dose of 800 mg daily in patients
weighing ≥50 kg receiving rifampin [27]. The basis for these rec-
ommendations is pharmacokinetic studies that have shown an
increase in efavirenz apparent oral clearance and a reduction in
efavirenz concentrations by approximately 30%, and an attempt
to minimize the potential for subtherapeutic concentrations by
increasing the dose of efavirenz [28]. A number of clinical trials,
however, have shown sustained virologic efficacy during concom-
itant standard-dose efavirenz and rifampin therapy [29–32].
Nonetheless, the lack of any pharmacokinetic and pharmacody-
namic data when daily rifapentine is given with efavirenz has pre-
cluded a recommendation for coadministration in HIV-infected
individuals on ART.
The challenges of concomitant therapy for HIV infection and
LTBI are not trivial. Current treatment options for LTBI in pa-
tients receiving ART are limited to ≥6 months of daily isoniazid
preventive therapy. Despite the demonstrated efficacy of isoniazid
preventive therapy, poor rates of uptake and the high proportion
of individuals who fail to complete even 6 months of isoniazid
preventive therapy highlight the need for alternative, more effec-
tive short-course approaches for treatment of LTBI [33]. ACTG
A5279 represents an effort to extend the benefits of a novel,
short-course rifapentine-containing regimen for LTBI treatment
to HIV-infected individuals on ART. We chose to study the rifa-
pentine–efavirenz interaction in this intended patient population,
rather than the more common evaluation of drug–drug interac-
tions in healthy volunteers. To accomplish this, we used a conve-
nient and minimally invasive pharmacokinetic sampling strategy.
Published data support a single mid-dosing interval efavirenz
concentration as informative of the pharmacokinetics and phar-
macodynamics of efavirenz [14]. Efavirenz is typically dosed
prior to bedtime; therefore, a 12-hour postdose sampling time
also was convenient for the participants and the clinical sites.
Bayesian analysis allowed us to evaluate the sparse individual par-
ticipant pharmacokinetic data as it accrued, instead of after com-
plete enrollment. This enabled early protocol stopping rules to
limit enrollment had a clinically significant decrease in efavirenz
concentrations been detected. The measurement of plasma HIV-
1 RNA before and after rifapentine provided a pharmacodynamic
endpoint. These characteristics of this clinical pharmacologic
evaluation, designed as a companion to the larger A5279 clinical
trial, illustrate how necessary drug–drug interaction information
can be efficiently and safely obtained. Our finding that a 4-week
regimen of daily rifapentine and isoniazid can be administered to
HIV-infected persons who are receiving an efavirenz-containing
antiretroviral drug regimen, without clinically meaningful reduc-
tions in efavirenz concentrations or virologic suppression, is one
important step that advances the field of concomitant therapy for
HIV infection and latent tuberculosis.
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